Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.

Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, Safina A, Sviridov S, Koman IE, Veith J, Komar AA, Gudkov AV, Gurova KV.

Sci Transl Med. 2011 Aug 10;3(95):95ra74. doi: 10.1126/scitranslmed.3002530.

2.

9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.

Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, Gurova KV.

Oncogene. 2009 Feb 26;28(8):1151-61. doi: 10.1038/onc.2008.460. Epub 2009 Jan 12.

PMID:
19137016
3.

Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation.

Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, Komarova EA, Gudkov AV.

Nat Chem Biol. 2006 Sep;2(9):474-9. Epub 2006 Jul 23.

PMID:
16862141
4.

Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors.

Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV.

Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17448-53. Epub 2005 Nov 15.

Supplemental Content

Loading ...
Support Center